Erratum: Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes (Current Atherosclerosis Reports (2013) 15:6 (327) DOI: 10.1007/s11883-013-0327-7);Anti-inflammatory strategies for plaque stabilization after acute coronary syndromes topical collection on vascular biology

Current Atherosclerosis Reports

Volumn 15, Issue 6, 2013, Pages 374-

  Baruch, Amos ^a   Van Bruggen, Nicholas ^a   Kim, Juyong Brian ^b   Lehrer Graiwer, Joshua E ^a  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndrome; Inflammation; Plaque stabilization; Therapeutics; Vulnerable plaque

Indexed keywords

ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1; ATI 5261; CANAKINUMAB; CD14 ANTIGEN; CD16 ANTIGEN; CER 001; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; COR 2; CSL 112; DARAPLADIB; ELAFIN; GAMMA INTERFERON; GSK 2586681; GSK 2586881; INTERLEUKIN 1B ANTIBODY; INTERLEUKIN 7; INV 311; LOSMAPIMOD; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; OPN 305; P SELECTIN GLYCOPROTEIN LIGAND 1; PA 508; RECEPTOR ANTIBODY; RVX 208; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 ANTIBODY; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VBL 201;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUTOPHAGY; CARDIOVASCULAR RISK; CELL MIGRATION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; LIPID OXIDATION; MONOCYTE; MONOCYTOSIS; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SMOOTH MUSCLE FIBER; STABLE ANGINA PECTORIS; STEM CELL NICHE; STRESS; T LYMPHOCYTE; TISSUE INJURY; UNSTABLE ANGINA PECTORIS; CORONARY ARTERY DISEASE; HEART INFARCTION; IMMUNOLOGY; REVIEW; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC;

ACUTE CORONARY SYNDROME; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC;

EID: 84878108345     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-013-0374-0     Document Type: Erratum

References (97)

1. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med. 2000;343(13):915-22.
2. Milonas C et al. Effect of angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol. 2010;105:1229-34.
3. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol. 1979;44(1):53-9. (Pubitemid 9216892)
4. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, Mehran R, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364(3):226-35. This article prospectively followed the progression of plaques in patients with acute coronary syndrome (ACS) for median of 3.4 years using coronary angiography and radiofrequency intravascular ultrasound. Major finding was that the non-culprit lesions for initial ACS event were equally likely to cause major cardiovascular adverse events. These lesions were mostly angiographically mild but had characteristics of vulnerable plaque, including thin-cap fibroatheromas, large plaque burden or small luminal area.
5. Virmani R, Burke AP, Farb A. Plaque morphology in sudden coronary death. Cardiologia. 1998;43(3):267-71.
6. Kato Y, Yonetsu T, Kim S, Xing L, Lee H, McNulty I, et al. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012;5:433-40.
7. Rioufol G, Finet G, Ginon I, André-Fouët X, Rossi R, Vialle E, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106:804-8.
8. MacNeill BD, Jang IK, Bouma BE, et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol. 2004;44(5):972-9. (Pubitemid 39165129)
9. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109:II2-10.
10. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279(20):1643-50. (Pubitemid 28248591)
11. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4:977-87.
12. Nissen E, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071-80. (Pubitemid 38541684)
13. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. For the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
14. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. J Am Coll Cardiol. 2005;46(8):1405-10. (Pubitemid 41446173)
15. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. For the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-8. (Pubitemid 32259905)
16. Wilbert-Lampen U, Nickel T, Leistner D, Güthlin D, Matis T, Völker C, et al. Modified serum profiles of inflammatory and vasoconstrictive factors in patients with emotional stress-induced acute coronary syndrome during World Cup Soccer 2006. J Am Coll Cardiol. 2010;55(7):637-42.
17. Steptoe A, Wikman A, Molloy GJ, Messerli-Bürgy N, Kaski JC. Inflammation and symptoms of depression and anxiety in patients with acute coronary heart disease. Brain Behav Immun. 2012. doi: 10.1016/j.bbi.2012.09.002. This study supports the concept that inflammatory cytokines and leukocytosis are related to stress and anxiety.
18. Nahrendorf M, Pittet MJ, Swirski FK. Monocytes: protagonists of infarct inflammation and repair after myocardial infarction. Circulation. 2010;121(22):2437-45.
19. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, et al. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: a possible role for left ventricular remodeling. J Am Coll Cardiol. 2002;39(2):241-6. (Pubitemid 34084628)
20. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T, et al. Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol. 2009;54(2):130-8.
21. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204(12):3037-47. (Pubitemid 350179569)
22. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012;209(1):123-37. The spleen hosts niches for extramedullary emergency monocytopoiesis that are important to the infarct healing process, but can also contribute to the risk of ASC recurrence in cases where the kinetics of monocyte response is altered.
23. Aoki S, Nakagomi A, Asai K, Takano H, Yasutake M, Seino Y, et al. Elevated peripheral blood mononuclear cell count is an independent predictor of left ventricular remodeling in patients with acute myocardial infarction. J Cardiol. 2011;57(2):202-7.
24. Shantsila E, Lip GY. Monocytes in acute coronary syndromes. Arterioscler Thromb Vasc Biol. 2009;29(10):1433-8.
25. Rogacev KS, Cremers B, Zawada AM, Seiler S, Binder N, Ege P, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512-20.
26. Kashiwagi M, Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Ozaki Y, et al. Association of monocyte subsets with vulnerability characteristics of coronary plaques as assessed by 64-slice multidetector computed tomography in patients with stable angina pectoris. Atherosclerosis. 2010;212(1):171-6. Strong association between circulating CD14+CD16+ monocytes and the presence of vulnerable plaques in angina patients suggests potential link between monocyte response post ACS and risk of event recurrence.
27. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Ishibashi K, Komukai K, et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis. 2010;212(2):628-35. Circulating CD14+CD16+CX3CR1+ monocytes were in strong correlation with reduced fibrous cap thickness as measured by intravascular optical coherence tomography (OCT) in patients admitted with unstable angina. Provides a link between monocyte response post ACS and plaque vulnerability.
28. Assmus B, Iwasaki M, Schächinger V, Roexe T, Koyanagi M, Iekushi K, et al. Acute myocardial infarction activates progenitor cells and increases Wnt signalling in the bone arrow. Eur Heart J. 2012;33(15):1911-9. AMI increases the number of CD34+ and CD133+ bone marrow cells within 7 days provides a potential link between catecholamine action following ACS and progenitor response in the bone marrow through Wnt signaling.
29. Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26(12):1196-204. (Pubitemid 40863126)
30. Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood. 2005;105(1):199-206. (Pubitemid 40053083)
31. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011;11(11):762-74.
32. Combadière C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117(13):1649-57. (Pubitemid 351482605)
33. Liaudet L, Rosenblatt-Velin N. Role of innate immunity in cardiac inflammation after myocardial infarction. Front Biosci (Schol Ed). 2013;5:86-104.
34. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161-6.
35. •• Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, Lipuma L, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity. 2011;34(4):590-601. Very low levels of circulating TLR ligands promote the release of bone marrow monocytes into the circulation, providing a possible mechanistic insight into the communication between remote sites of injury or inflammation and bone marrow responses.
36. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407-21. (Pubitemid 43121987)
37. •• Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487(7407):325-9. A provocative hypothesis of the mechanisms associated with event recurrence following acute coronary syndrome. The paper establishes the foundation for the understanding of increased CV risk in ACS patients and the potential therapeutic avenues to tackle such risk.
38. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325:612-6.
39. Leuschner F, Panizzi P, Chico-Calero I, Lee WW, Ueno T, Cortez-Retamozo V, et al. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ Res. 2010;107(11):1364-73.
40. Robinette CD, Fraumeni Jr JF. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet. 1977;ii:127-9. (Pubitemid 8124956)
41. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, et al. MLN1202 Study Group. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011;107(6):906-11. The only clinical study to date that demonstrates the potential contribution of CCR2 to the pro-inflammatory condition in patients with CV disease.
42. Hotchi J, Hoshiga M, Takeda Y, Yuki T, Fujisaka T, Ishihara T, et al. Plaque-stabilizing effect of angiotensin-converting enzyme inhibitor and/or angiotensin receptor blocker in a rabbit plaque model. J Atheroscler Thromb. 2013;20(3):257-66.
43. Kuhnast SB, van der Hoorn JWA, van den Hoek AM, Havekes LM, Liau G, Jukema JW, et al. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden. CETP transgenic mice with or without treatment with atorvastatin. J Hypertens. 2012;30(1):107-16.
44. 2-dependent matrix metalloproteinase activity. Circulation. 2004;109:1482-8. (Pubitemid 38420175)
45. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedeberg's Arch Pharmacol. 2004;369:151-9. (Pubitemid 38270770)
46. Yonekawa K, Neidhart M, Altwegg LA, Wyss CA, Corti R, Vogl T, et al. Myeloid related proteins activate Toll-like receptor 4 in human acute coronary syndromes. Atherosclerosis. 2011;218(2):486-92.
47. Kashiwagi M, Imanishi T, Ozaki Y, Satogami K, Masuno T, Wada T, et al. Differential expression of Toll-like receptor 4 and human monocyte subsets in acute myocardial infarction. Atherosclerosis. 2012;221(1):249-53. Increased TLR4 expression levels on CD14+CD16+ monocytes at the culprit site in patients with ACS, suggesting the involvement of specific monocyte subsets in plaque destabilization.
48. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005;111(20):2654-61. (Pubitemid 40740866)
49. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ER. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol. 2005;45(12):1939-45. (Pubitemid 40814112)
50. Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, et al. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol. 2006;109(2):226-34.
51. Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, et al. Enhanced response of blood monocytes to in vitro lipopolysaccharide- challenge in patients with recurrent unstable angina. Circulation. 2001;103(18):2236-41. (Pubitemid 32433711)
52. Iyer SS, Pulskens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci U S A. 2009;106(48):20388-93.
53. Kawaguchi M, Takahashi M, Hata T, Kashima Y, Usui F, Morimoto H, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123(6):594-604.
54. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515-81.
55. Pasqui AL, Di Renzo M, Bova G, Maffei S, Pompella G, Auteri A, et al. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med. 2006;6(1):38-44.
56. Felge E et al. Modified phospholipids as anti-inflammatory compounds. Curr Opin Lipidol. 2010;21(6):525-9.
57. Ridker PM et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162(4):597-605.
58. De Palma R, Del Galdo F, Abbate G, Chiariello M, Calabró R, Forte L, et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation. 2006;113(5):640-6.
59. Gotsman I, Sharpe AH, Lichtman AH. T-cell costimulation and coinhibition in atherosclerosis. Circ Res. 2008;103(11):1220-31.
60. Zhao Z, Wu Y, Cheng M, Ji Y, Yang X, Liu P, et al. Activation of Th17/Th1 and Th1, but not Th17, is associated with the acute cardiac event in patients with acute coronary syndrome. Atherosclerosis. 2011;217(2):518-24. IFNg-producing Th1 cells the can also release IL-17 are implicated in ACS. This paper highlights the imbalance in T cell response following ACS, and suggests the potential involvement of pro-inflammatory T cells in the development of atherosclerotic plaque instability.
61. Mor A, Luboshits G, Planer D, Keren G, George J. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 2006;27(21):2530-7. (Pubitemid 44627295)
62. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation. 1999;100(21):2135-9.
63. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002;105(5):570-5. (Pubitemid 34123430)
64. Nakajima T, Goek O, Zhang X, Kopecky SL, Frye RL, Goronzy JJ, et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res. 2003;93(2):106-13. (Pubitemid 36919697)
65. Liuzzo G, Biasucci LM, Trotta G, Brugaletta S, Pinnelli M, Digianuario G, et al. Unusual CD4 + CD28null T lymphocytes and recurrence of acute coronary events. J Am Coll Cardiol. 2007;50(15):1450-8. (Pubitemid 47494592)
66. Dumitriu IE, Baruah P, Finlayson CJ, Loftus IM, Antunes RF, Lim P, et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4 + CD28null T cells inpatients with acute coronary syndrome. Circ Res. 2012;110(6):857-69.
67. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost. 2009;7 Suppl 1:332-9.
68. Gómez-Guerrero C, Mallavia B, Egido J. Targeting inflammation in cardiovascular diseases. still a neglected field? Cardiovasc Ther. 2012;30(4):e189-97. doi: 10.1111/j.1755-5922.2011.00274.x.
69. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685-95. (Pubitemid 40530235)
70. Spann NJ, Garmire LX, McDonald JG, Myers DS, Milne SB, Shibata N, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell. 2012;151(1):138-52.
71. Tabas L. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10(1):36-46.
72. van Gils JM, Derby MC, Fernandes LR, Ramkhelawon B, Ray TD, Rayner KJ, et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol. 2012;13(2):136-43.
73. Björkerud S, Björkerud B. Am J Pathol. 1996;149(2):367-80.
74. Saso L, Firuzi O, Miri R, Tavakkoli M. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;25:3871-88.
75. Merched AJ, Williams E, Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler Thromb Vasc Biol. 2003;23(9):608-14. (Pubitemid 37108205)
76. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol. 2005;25(1):174-9. (Pubitemid 40054272)
77. Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol. 2005;25(11):2255-64. (Pubitemid 41552640)
78. Hotamisligil GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med. 2010;16(4):396-9.
79. Schrijvers DM, De Meyer GR, Martinet W. Autophagy in atherosclerosis: a potential drug target for plaque stabilization. Arterioscler Thromb Vasc Biol. 2011;31(12):2787-91.
80. Ouimet M, Franklin V, Mak E, Liao X, Tabas I, Marcel YL. Autophagy regulates cholesterol efflux from macrophage foam cells via lysosomal acid lipase. Cell Metab. 2011;13(6):655-67.
81. Tardif JC, L'Allier PL, Grégoire J, Ibrahim R, McFadden G, Kostuk W, et al. A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circ Cardiovasc Interv. 2010;3(6):543-8.
82. Dong B, Zhang C, Feng JB, Zhao YX, Li SY, Yang YP, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28(7):1270-6.
83. Rosenson RS, Brewer Jr HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125(15):1905-19.
84. Nissen SE et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292-300. (Pubitemid 37430562)
85. Vucic E, Rosenson RS. Recombinant high-density lipoprotein formulations. Curr Atheroscler Rep. 2011;13(1):81-7.
86. O'Donoghue ML, Braunwald E, White HD, Serruys P, Steg PG, Hochman J, et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. Am Heart J. 2011;162(4):613-619.e1.
87. Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172-82.
88. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012;53(9):1767-82.
89. Verheye S. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol. 2007;49(6): 798706-15
90. Bailey D et al. A small molecule that increases apolipoprotein a-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55(23):2580-9.
91. Grommes J et al. Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury. Am J Respir Crit Care Med. 2012;185(6):628-36.
92. Bhaskar V et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis. 2011;216(2):313-20.
93. Arsian F et al. Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012;5(2):279-87.
94. Melloni C et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. Am Heart J. 2012;164(5):646-53.
95. Liehn EA et al. A New Monocyte chemotactic protein-1/Chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol. 2010;56(22):1847-57.
96. Khuseyinova N et al. Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in? Mol Diagn Ther. 2007;11(4):203-17. (Pubitemid 47359073)
97. Li JS, Jaggers J, Anderson PA. The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert Rev Cardiovasc Ther. 2006;4(5):649-54. (Pubitemid 44734235)